|Title:|| Antifungal compositions with improved bioavailability|
|Abstract:||The present invention is concerned with novel pharmaceutical compositions of itraconazole which can be administered to a mammal suffering from a fungal infection, whereby a single such dosage form can be administered once daily, and in addition at any time of the day independently of the food taken in by said mammal. These novel compositions comprise particles obtainable by melt-extruding a mixture comprising itraconazole and an appropriate water-soluble polymer and subsequently milling said melt-extruded mixture.|
|Inventor(s):|| Baert; Lieven Elvire Colette (Bruges, BE), Verreck; Geert (Malle, BE), Thone; Dany (Beerse, BE) |
|Assignee:|| Janssen Pharmaceutica N.V. (Beerse, BE) |
1. A pharmaceutical dosage form comprising a therapeutically effective amount of particles consisting of a solid dispersion comprising (a) itraconazole, or one of its
stereoisomers, or a mixture of two or three or four of its stereoisomers, and (b) one or more pharmaceutically acceptable water-soluble polymers; wherein the particle has a size of less than 600 .mu.m; the solid dispersion is in the form of a solid
solution comprising (a) and (b), or in the form of a dispersion wherein amorphous or microcrystalline (a) or amorphous or microcrystalline (b) is dispersed in a solid solution comprising (a) and (b) and the water-soluble polymer is a polymer that has an
apparent viscosity of 1 to 100 mPa.s when dissolved in a 2% aqueous solution at 20.degree. C. solution, and wherein the dosage form further comprises by weight based on the total weight of the dosage form: 21.65% itraconazole 32.48% HPMC 2910 5 mPa.s
30.57% spray-dried lactose monohydrate:microcrystalline cellulose (75:25) mixture 8.49% crospovidone 2.79% talc 0.93% hydrogenated vegetable oil Type I 0.28% colloidal anhydrous silica 0.24% magnesium stearate, yielding 97.43% tablet core, and 1.47% HPMC
2910 5 mPa.s 0.37% propyleneglycol 0.29% talc 0.44% titanium dioxide, yielding 2.57% film-coat.
2. A method of treating a fungal infection in a mammal comprising orally administering to the mammal an effective antifungal amount of itraconazole in a pharmaceutical dosage form as claimed in claim 1, wherein said pharmaceutical dosage form
can be administered once daily.
3. The method of claim 2, wherein said pharmaceutical dosage form can be administered at any time of the day independently of the food taken in by said mammal.